MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.08
-0.48
-4.55%
Closed 16:01 10/28 EDT
OPEN
10.34
PREV CLOSE
10.56
HIGH
10.55
LOW
9.92
VOLUME
530.83K
TURNOVER
--
52 WEEK HIGH
17.95
52 WEEK LOW
3.580
MARKET CAP
318.20M
P/E (TTM)
-9.8785
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BrainStorm Cell recruits manufacturing partner for stem cell therapies for neurodegenerative disorders
BrainStorm Cell Therapeutics ([[BCLI]] -5.0%) partners with Rapid Reshore & Development ((RR&D)) to expedite site selection and design services for manufacturing facility for NurOwn in the U.S.The ~50K square-foot building will contain
Seekingalpha · 2d ago
BrainStorm Selected RR&D to Expedite Site Selection and Design Services for its Manufacturing Facility for NurOwn in the U.S.
Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI) announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S.
Benzinga · 2d ago
Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility
Rapid Reshore & Development (RR&D), an alliance of three specialized firms, and BrainStorm Cell Therapeutics, Inc (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced that BrainStorm has selected RR&D as its partner to expedite site selection and design services for a state-of-the-art manufacturing facility for NurOwn® (autologous MSC-NTF) in the U.S.
PR Newswire · 2d ago
BCLI: Manufacturing Agreement with Catalent; Recent Sell-off Unwarranted
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Manufacturing Agreement with Catalent On October 22, 2020, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced an agreement with Catalent, Inc. (CTLT) for the manufacture of NurOwn®, which is currently being evaluated in a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). The
Zacks Small Cap Research · 5d ago
Align Technology, Bio-Path Holdings leads healthcare gainers; InVivo Therapeutics, Teligent among major losers
Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Aptinyx (APTX) -21%, Iterum Therapeutics (ITRM) -20%, Timber Pharmaceuticals (TMBR) -18%.
Seekingalpha · 6d ago
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced an agreement for the manufacture of NurOwn®, BrainStorm’s autologous cellular therapy being investigated for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease or motor neuron disease. NurOwn induces mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs) known to promote the survival of neurons and neuroprotection. The therapy has received Fast Track status from the U.S. FDA for ALS and has also been granted Orphan Drug Status for ALS by both the FDA and the European Medicines Agency. BrainStorm is currently completing a 200-patient, double-blind, placebo-controlled, repeat-dosing NurOwn Phase 3 study in the U.S.As part of its commitment, Catalent will undertake the transfer of the manufacturing process to, and provide future CGMP clinical supply of NurOwn from, its new, 32,000 square-foot cell therapy manufacturing facility in Houston, Texas. On completion of the clinical trials and in anticipation of potential approval of NurOwn, the companies will look to extend the partnership to include commercial supply from the Houston facility.“We are proud to have a partner in Catalent whose excellence in manufacturing quality therapies will support commercial supply of NurOwn,” said Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics. “We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.”Manja Boerman, Ph.D., President, Catalent Cell & Gene Therapy, said, “Our experience in cell therapy development, and the manufacturing capabilities that our newly constructed, state-of-the-art facility in Houston offers, position us to best support BrainStorm, with its leading therapeutic candidate for ALS treatment. We look forward to partnering with BrainStorm and providing our stem cell manufacturing expertise as we work to optimize production and streamline the product’s path towards commercial launch.”About Catalent Cell & Gene TherapyWith deep experience in viral vector scale-up and production, Catalent Cell & Gene Therapy is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies. When it acquired MaSTherCell, Catalent added expertise in autologous and allogeneic cell therapy development and manufacturing to position it as a premier technology, development and manufacturing partner for innovators across the entire field of advanced biotherapeutics. Catalent has a global cell and gene therapy network of dedicated, large-scale clinical and commercial manufacturing facilities, and fill-finish and packaging capabilities located in both the U.S. and Europe. An experienced partner, Catalent Cell & Gene Therapy has worked with industry leaders across 70+ clinical and commercial programs.About CatalentCatalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.comMore products. Better treatments. Reliably supplied.™About NurOwn®NurOwn® (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) completed enrollment in August 2020. For more information, visit the company's website at www.brainstorm-cell.com.Safe-Harbor Statement Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn® treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at https://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.Media Contacts:        Catalent   BrainStorm Cell Therapeutics Chris Halling +44 (0)7580 041073 chris.halling@catalent.com Richard Kerns +44 (0) 161 728 5880 richard@nepr.agency Investor Relations: Corey Davis, Ph.D. LifeSci Advisors, LLC Phone: +1 646-465-1138 cdavis@lifesciadvisors.com           Media: Paul Tyahla SmithSolve Phone: + 1.973.713.3768 Paul.tyahla@smithsolve.com
GlobeNewswire · 6d ago
Catalent, BrainStorm Cell Therapeutics Report Partnership To Manufacture Mesenchymal Stem Cell Platform, NurOwn, No Terms Disclosed
Catalent (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and BrainStorm
Benzinga · 6d ago
NNDM, CIH, BCLI and CBLI among midday movers
Gainers: Cleveland BioLabs (CBLI) +66%.9F (JFU) +47%.Molecular Data (MKD) +35%.Natuzzi (NTZ) +30%.Aptinyx (APTX) +26%.VOXX International (VOXX) +23%.Pro-Dex (PDEX) +21%.SunLink Health Systems (SSY) +21%.China Index Holdings (CIH) +14%.Anchiano Therapeutics (ANCN) +11%.Losers: Kaixin Auto
Seekingalpha · 10/20 16:38
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCLI. Analyze the recent business situations of Brainstorm Cell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCLI stock price target is 26.00 with a high estimate of 33.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 99
Institutional Holdings: 6.79M
% Owned: 21.50%
Shares Outstanding: 31.57M
TypeInstitutionsShares
Increased
21
2.41M
New
40
910.54K
Decreased
12
786.75K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-2.11%
Key Executives
Chairman/Director
Jacob Frenkel
President
Ralph Kern
Chief Executive Officer
Chaim Lebovits
Vice Chairman/Director
Irit Arbel
Chief Financial Officer/Executive Vice President/Treasurer
Preetam Shah
Chief Operating Officer/Executive Vice President
David Setboun
Executive Vice President/Director
Uri Yablonka
Executive Vice President
Stacy Lindborg
Executive Vice President
Anthony Waclawski
Other
Arturo Araya
Director
Sankesh Abbhi
Independent Director
June Almenoff
Independent Director
Anthony Polverino
Independent Director
Malcolm Taub
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.